CD70 and neoplasm: In summary, we have successfully developed a CD70-targeting allogeneic CAR-T cell therapy, termed SAP UCAR-T, which demonstrated enhanced in vivo persistence and tumor-eliminating ability, along with minimal safety concerns in preclinical evaluations.